Acousia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acousia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acousia Today - Breaking & Trending Today

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Published: February 15, 2024

Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).

Source: prleap.com

Related Topics:

Acousia Therapeutics GmbH: Hearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11-15

Published: November 24, 2022

TÜBINGEN, Germany, Nov. 24, 2022 /PRNewswire/ -- Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department

Source: finanznachrichten.de

Related Topics:

Kostenloser Wertpapierhandel Tim Boelke Hearing Research Center Department Of Otolaryngology Midwinter Meeting Of The Association For Research Translational Hearing Research Group Therapeutics Gmbh Hearing Research Center Neck Surgery Annual Midwinter Meeting Against Cisplatin Induced Hearing Loss Outer Hair Cell Death Guinea Pig Winter Meeting Drug Candidate Age Related Hearing Loss

Acousia Therapeutics GmbH: Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston

Published: May 11, 2022

TÜBINGEN, Germany, May 11, 2022 /PRNewswire/ -- Acousia Therapeutics GmbH will be presenting data on the company's clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd

Source: finanznachrichten.de

Related Topics:

United States Kostenloser Wertpapierhandel Hanson Wade Tim Boelke Jonas Dyhrfjeld Johnsen Early Development Current Inner Ear Therapeutic Development Pathway Therapeutics Gmbh Inner Ear Therapeutics Summit Chief Development Officer Early Development Process Minimize Setbacks Faced Calling Out

Acousia Therapeutics GmbH: Hearing loss company Acousia Therapeutics: first patient with age-related hearing loss treated with ACOU085

Published: May 5, 2022

TÜBINGEN, Germany, May 5, 2022 /PRNewswire/ -- ACOU085, the lead candidate from Acousia Therapeutics, has been administered to the first patient with age-related hearing loss (presbycusis) in

Source: finanznachrichten.de

Related Topics:

Kostenloser Wertpapierhandel Tim Boelke Department Of Otolaryngology Head Neck Surgery Of The University Acousia Therapeutics German Bfarm Chief Executive Officer Chief Medical Officer Neck Surgery Therapeutics Gmbh

Acousia Therapeutics GmbH: Hearing loss company Acousia Therapeutics to present data for ACOU085 at ARO 2022 MidWinter Meeting February 5-9

Published: February 4, 2022

TÜBINGEN, Germany, Feb. 4, 2022 /PRNewswire/ -- Acousia Therapeutics GmbH - along with its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department

Source: finanznachrichten.de

Related Topics:

Peixoto Pinheiro Kostenloser Wertpapierhandel Tim Boelke Synovo Gmb Hearing Research Center Department Of Otolaryngology Midwinter Meeting Of The Association For Research Translational Hearing Research Group Translational Development Therapeutics Gmbh Hearing Research Center Neck Surgery Synovo Gmbh Annual Midwinter Meeting Winter Meeting Protects Against Outer Hair Cell Loss Age Related Hearing Loss Cisplatin Induced Hearing Loss Acousia Therapeutics Gmbh

Page 2 Page 3 Page 4 Page 5